Reckitt Benckiser to pay $1.4bn fine over opioid treatment sales

768.jpg?width=300&quality=85&auto=format

Nurofen maker reaches deal with US over alleged fraudulent marketing of Suboxone

Reckitt Benckiser has agreed to pay a $1.4bn (£1.1bn) fine to settle a US investigation into sales of a treatment for addiction to opioids by its former prescription drugs business Indivior.

The maker of Nurofen and Durex said it had reached a deal with the US Department of Justice and Federal Trade Commission to resolve the long-running inquiry into sales and marketing of Suboxone Film, an opioid-based drug.

Continue reading…